Rankings
▼
Calendar
URGN Q4 2016 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$918M
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$18M
Gross Profit
$18M
99.8% margin
Operating Income
$14M
79.3% margin
Net Income
$12M
70.2% margin
EPS (Diluted)
$1.18
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
$13M
Free Cash Flow
$13M
Stock-Based Comp.
$581,000
Balance Sheet
Total Assets
$23M
Total Liabilities
$7M
Stockholders' Equity
$16M
Cash & Equivalents
$21M
← FY 2016
All Quarters
Q1 2017 →
